
In an interview, Kami J. Maddocks, MD, details therapies that may shake up the standard of care in lymphoma going forward.

Your AI-Trained Oncology Knowledge Connection!


In an interview, Kami J. Maddocks, MD, details therapies that may shake up the standard of care in lymphoma going forward.

In an interview, Kami J. Maddocks, MD, showed her excitement about future use of bispecific antibodies for the treatment of lymphomas.

Kami J. Maddocks, MD, reviews updates to a pivotal trial supporting the use of brentuximab vedotin in advanced-stage Hodgkin lymphoma and ongoing research into PD-1 inhibitors in this space.

Kami J. Maddocks, MD, reviews findings from the SHINE trial comparing ibrutinib plus bendamustine/rituximab vs bendamustine/rituximab alone in newly diagnosed mantle cell lymphoma.

Kami J. Maddocks, MD, talks CAR T-cell therapy approvals for the treatment of relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma plus a new treatment supplanting R-CHOP.

Gilles Salles, MD, PhD, and Kami Maddocks, MD, discuss relapsed/refractory diffuse large B-cell lymphoma therapeutic options and important data from the L-MIND trial.

CancerNetwork® speaks with Kami Maddocks, MD, in part 2 of a 3-part series on CD19–directed agents and other second-line agent for relapsed/refractory diffuse large B-cell lymphoma.

Published: August 30th 2021 | Updated:

Published: July 30th 2021 | Updated:

Published: September 12th 2022 | Updated:

Published: September 1st 2022 | Updated: